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Introduction
From 19–22 June 2007, an international workshop on neuropathology in leprosy was held at
the Kontakt der Kontinenten conference centre, Soesterberg, the Netherlands. The workshop
was organised by the Netherlands Leprosy Relief and the Synapse Consortium for research on
nerve damage and reactions in leprosy. The workshop brought together 36 scientists and experts
from 11 countries in North and South America, Europe, Africa and Asia (see Appendix 3)
(Table A4). They represented many professional disciplines, including neurologists,
neurosurgeons, neurophysiologists, neuropathologist, clinical immunologists, histopathologists,
leprologists, epidemiologists, statisticians, a research physiotherapist and a dermatologist.
Structure of the Report
Part 1 of the report comprises a summary of salient points noted during the presentation of
research findings and the plenary discussions that followed each presentation. Part 2 is made
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up of the consensus statements of the three working groups that met on Day 3 and 4 of the
workshop. They attempted to reach consensus on current understanding and best practice
based on available evidence, identify gaps in knowledge and prioritise research needs for the
future. They addressed the following topics:
Group 1: Mechanisms of neuropathology in leprosy
Group 2: Screening and diagnostic testing of nerve function in leprosy
Group 3: Treatment of neuropathy in leprosy
Part 1 – Plenary Sessions’ Report
The workshop started with a warm welcome by the convener, Dr Wim van Brakel, and by
Mr. Kommer Braber, Director of Netherlands Leprosy Relief (NLR), the sponsoring agency.
Although not able to be present in person, Dr Pannikar of the WHO Leprosy Unit expressed
his full support for the effort to understand the neuropathology of leprosy more fully.
Prof. Cairns Smith reviewed the objectives of the workshop; he pointed out that the
synthesis of neuro-immunopathological, clinical and epidemiological regarding the
neuropathology of leprosy evidence was the key process in this workshop:
1. To bring together and discuss the evidence available from different studies on the neuro-
immunopathology of leprosy and develop consensus on the current best model(s) of
neuropathy in leprosy.
2. To bring together and discuss the evidence available from different clinical and
epidemiological studies on the neuropathology of leprosy and develop consensus on the
risk factors for and pattern of neuropathy in leprosy.
3. To integrate the conclusions from 1 and 2 and to discuss the implications of current
knowledge for treatment and management of neurological complication in leprosy.
4. To produce a consensus report on ‘the current model of neuropathology in leprosy and its
implications for the treatment of nerve damage’.
5. To develop an agenda for future research and action regarding neurological aspects in
leprosy.
Two reviews were presented, firstly of relevant clinical and epidemiological research by
Dr Paul Saunderson and, secondly, of recent neuropathological research by Dr David
Scollard. They are to be published separately. It is clear that previous studies have used
different definitions for clinical aspects of neuropathy in leprosy, but recent papers by
Nicholls and van Brakel should help to standardise these in future.1 A review of the
neuropathology showed that the relative importance of the immunological and non-
immunological mechanisms of nerve damage is still poorly understood, which has important
implications for treatment (Scollard, submitted). In addition, a number of processes, such as
the development of oedema in and around the nerves, are known to be important, but have not
been studied in any depth up to now.
New findings from the recently completed INFIR study were presented.2 Approximately
300 MB leprosy patients were extensively investigated for risk factors for, and immuno-
pathological features of, nerve damage. An interesting finding was that histology correlated
rather poorly with the clinical features seen in patients in reaction (Lockwood et al.,
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in preparation). Two-thirds of the reaction diagnoses were only histopathological reactions
(‘silent reaction’), which were not diagnosed clinically. It was suggested that the whole
pathological process in leprosy is in fact an immunological reaction, which sometimes
surfaces as a clinical ‘reaction’. This is confirmed by immunohistochemical evidence
showing that reactional markers (CD68, TNF-alpha, iNOS and TGF-beta) were present in the
large majority of BT/BL patients, but were increased in Type 1 Reactions (T1R).
The use of various modalities for testing nerve function was also examined in the INFIR
study. There was a presentation and discussion about the need to establish normative ranges
or cut-offs for various tests and about the importance of taking into account simple
confounding factors, such as age and sex. The widely-used standard tests of sensation, the
graded monofilaments, generally reflected well the underlying severity of neuropathy
(measured with sensory nerve conduction and temperature sensation), though sometimes with
considerable delay (van Brakel et al., submitted). The common test of muscle strength, the
voluntary muscle test (VMT), reflected underlying neuropathy well in the ulnar nerve, but not
in the median or peroneal nerve. In the latter two nerves, less severe degrees of weakness are
being missed.2 It was suggested in the discussion that extension of the big toe may be a more
accurate test of peroneal nerve function than dorsiflexion of the foot. This requires further
study. From a prospective comparison of tests, nerve conduction studies and warm perception
testing appeared to be the most sensitive tests, allowing NFI to be detected early (van Brakel
et al., in preparation). Subclinical neuropathy was shown to be very extensive. Contrary to
expectations, the study did not find consistent evidence that small fibre neuropathy generally
precedes large fibre neuropathy.
Dr Peter Nicholls presented a novel graphical method of showing how nerve function and
laboratory parameters of individual INFIR patients changed over time. This was regarded as
very valuable, as it allowed insight into how different parameters related to each other in
time.
A number of presentations from FIOCRUZ, Brazil, presented various modalities for
testing, including the vasomotor reflex (VMR) as a test of autonomic nerve function.3 In a
group of 76 patients, autonomic nerve lesion was more frequent than somatic lesions and was
strongly related to the immune-inflammatory reaction against M. leprae. Measured by laser
Doppler fluxometry, household contacts of patients are at an increased risk of having
peripheral autonomic neuropathy as compared to the general population, but the importance
of this is unclear. One current study is evaluating the predictive value of abnormal VMRs and
presence of PGL-1 antibodies with regard to the risk of developing leprosy in household
contacts. Genetic studies have indicated a possible role of ninjurin as a predictive marker of
neuropathy.
Prof. Cairns Smith reviewed evidence from the ILEP Nerve Function Impairment and
Reaction (INFIR) study on predicting new NFI in people with leprosy (Smith et al., in
preparation). Interestingly, different predictors were found for skin events and nerve events.
Abnormalities in sensory nerve conduction parameters were the most sensitive predictors of
new NFI. The apparent predictive effect of some other tests, such as warm and cold sensation,
disappeared on adjusting for age. Of the serological markers, TNFa levels do show
significant within-subject change prior to an event, but the variation between individuals is
probably too great to allow a test to be developed.
Dr Jan Hendrik Richardus presented an analysis of data from the COLEP study, showing
that PGL-1 positivity, in combination with MB classification, was a better predictor of future
NFI than the previous clinical prediction rule from the BANDS study that combined MB
Wim H. van Brakel et al.418
classification and NFI already present at diagnosis.4 In discussion, it was pointed out that the
meaning of PGL-1 positivity in this context is unclear. No such association was found in the
INFIR study. This finding would need validation in other areas.
Electrophysiological data of nerve function in patients in the INFIR cohort treated with
corticosteroids were presented by Dr Einar Wilder-Smith. He showed a good response to
treatment with prednisolone in large fibre damage (sensory nerve conduction (SNC)
amplitude), but little response in small fibres (warm detection thresholds (WDT)). The
improvement was maximum after 6 months and was best in those with both amplitude and
latency impairment. In contrast, in a study of electrophysiological parameters in pure neural
leprosy patients treated with MDT and steroids in Brazil, presented by Dr Ximena
Illarramendi, small fibres showed some recovery after 1 year (autonomic function, and pain
and temperature sensation), while NC parameters did not, except for nerve conduction block.
Wilson Marques Junior presented data on electrophysiological abnormalities found in 332
household contacts of leprosy patients. Thirteen were diagnosed with various types of
neuropathy, but the predictive value of these findings for developing clinical leprosy is as yet
unsure. No predictive value could be established until now in another study in Brazil
investigating the risk of developing leprosy in contacts with abnormal vasomotor reflexes
(VMR) and a positive PGL-1 test.
Surgical decompression of affected nerves is enthusiastically advocated by some authors.
Published results were reviewed by Natasja van Veen, who showed that most studies were
methodologically unsound (van Veen et al., in preparation). Pain relief seems to be a definite
benefit of surgery, but improvement in nerve function has not been demonstrated. For future
studies, it was suggested that imaging of nerves and the measurement of intra-neural pressure
may provide helpful indicators, in addition to routine tests of nerve function and nerve
conduction studies.
Dr Elizabeth Bezuneh emphasised the importance of psychosocial issues in the
management of NFI. Low self-esteem and depression can prevent recovery by blocking
compliance with treatment. Counselling and the formation of self-care groups have been
helpful in some settings.
Dr Vanaja Shetty reviewed her work on the pathogenesis of neuropathy. She suggested
that atrophic changes in axons precede paranodal demyelination.5 Electron microscopy
studies showed a reduction in axon calibre. Hypophosphorylation of axons was consistently
found in nerves of leprosy-affected persons. This was proposed to be the mechanism
underlying axonal atrophy.
David Scollard presented recent work on the armadillo model of nerve damage, which
now seems quite promising. Finally, the bank of serological, biopsy materials and blots, from
the INFIR study, which are stored at BPRC, Hyderabad, India, was described by Prof. Indira
Nath. Participants were invited to submit proposals to use these specimens for further study.
The prospective nature of the study and the enormous database of clinical data, make this
‘bank’ a unique resource.
Part 2 – Consensus Statements of the Working Groups
MECHANISMS OF NEUROPATHY IN LEPROSY – GROUP 1
Three distinct mechanisms of nerve damage in leprosy are recognised:
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Damage due to direct effects of M. leprae
Damage due to direct effects of M. leprae includes neurofilament damage of the type
described by the models of Shetty et al.5 mechanisms involving Schwann cell pathology,6,7
and also the contact demyelination described by Rambukkana and colleagues.8 Investigations
of how and when demyelination occurs will need to involve the use of animal as well as in
vitro model systems.
Damage mediated by inflammatory and immune-mediated processes
Damage mediated by inflammatory and immune-mediated processes is probably the most
varied form of damage, and includes, but is not limited to, damage involving:9 – 11
a. binding of antibodies to neurofilaments
b. cytotoxicity
c. homing receptors to e.g. Schwann cells
d. alteration of the phosphorylation status of nerve proteins
e. binding of myelin-activated T-cells
f. molecular mimicry/autoimmunity
Experimental studies to investigate these forms of nerve damage would involve the use of
Schwann cells, endothelial cell and macrophages in in vitro systems. The role of Schwann
cells in nerve damage, whether as passive targets of M. leprae or in an active role, has been
extensively studied, though many questions remain.6,9,12 – 14
Damage due to oedema and mechanical processes
a. Schwann cell damage can render nerve fibres more liable to mechanical injury.
b. Intercellular (and perhaps also intracellular) oedema in the nerve trunk, whether with or
without protein ingress, can lead to compression of the nerve fibres. It is also likely that
compression of the blood vessels occurs, leading to ischemia and further damage
Investigation of these processes may involve the use of CT guided probes to measure
intraneural pressure in nerves in vivo.
It is possible that some clinically observed phenomena, such as variability of response to
steroid treatment, may be due in part to these different processes of nerve damage working in
different combinations in different people.
Research Priorities
1. Development of animal models
Mouse (both standard and generic knock-out (GKO)) and armadillo models should be
further deployed in the investigation of the mechanisms of nerve damage. It is recognised
that the use of these models will be limited to a small number of centres: collaboration
between relevant centres should be encouraged.
2. In vitro systems
The utilisation of culture systems in the investigation of leprosy nerve damage is
becoming more widespread, and should be encouraged. Cross fertilisation with other areas
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of in vitro research into neurological phenomena (e.g. nerve regeneration) will be
especially beneficial. It should be noted that the application of data obtained from these
systems to clinical questions may not always be straightforward. As M. leprae is
essentially a human pathogen, the use of human cells and cell lines is strongly
recommended. Variations in the viability status of bacteria within a population and the
predilection of M. leprae for lower temperatures should all be taken into account when
designing experiments.
3. Early nerve damage
Electrophysiological assessments have identified household contacts of leprosy
patients who have impaired nerve conduction and autonomic nerve function but no
clinical symptoms. These individuals should be studied more closely, as they are
postulated to represent the earliest detectable form of leprosy nerve damage. Novel
techniques such as nerve imaging should be utilised in these studies, although the
application of such technology in leprosy is still in the developmental stage. Standardised
protocols for the selection and storage of samples (e.g. biopsies) should be developed.
A statement on nerve biopsies is appended.
4. Reaction-related nerve damage
As the INFIR studies have shown, the important clinical phenomenon of reaction lends
itself to investigation, as many patients at risk of developing reaction are already under
treatment. Protocols to compare samples taken at baseline with those from the same
patients at the onset of a reactional event should be developed; novel techniques, such as
Luminex (for changes in the cytokine milieu) or microarrays (to detect changes in host
gene expression), allow the assessment of large numbers of parameters simultaneously,
and should be considered for inclusion in such analyses. It should be noted that
identification of markers of phenomena such as nerve damage and reaction is still
required: it is recommended that another practical workshop should be organised to decide
priorities in this area.
5. Genetic variability
Much work has been done on the role of genetic susceptibility to leprosy per se, but the
involvement of genetic variability in susceptibility to reaction or nerve injury needs to be
more closely investigated. There are a number of existing databanks of material which
should be studied in this regard. The technology for assessing genetic variability has
evolved rapidly. Variability in M. leprae strains and its relation to nerve damage also
needs to be investigated more fully.
IMPLICATIONS FOR SCREENING AND DIAGNOSTIC TESTING – GROUP 2
Nerve function assessment (NFA) is important for the diagnosis of leprosy per se, but has an
even more crucial role in the prevention and early treatment of nerve function impairment
(NFI) once specific multidrug therapy is started. The evidence available from different clinical
and epidemiological studies, as well as from the experience of the participants, demonstrated
that nerve function impairment and assessment is heterogeneous between and within the
different endemic countries, time-consuming and, in some aspects, subjective.2,15 – 18 To be
able to compare the different studies and to draw more accurate conclusions, consensus
regarding NFA is needed, including the number and type of nerves to be assessed and the
minimum testing parameters that would give adequate sensitivity to detect NFI.
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Nerve function testing will depend on the level of the health services. Two levels of
evaluation were discussed. The first level is that of field programmes or integrated services.
The second level is the referral centre or hospital where expertise is available to perform a
more thorough evaluation of the patient with additional examination techniques.
PERIPHERAL LEVEL (FIELD PROGRAMMES)
For this level, the number of parameters assessed should be minimised.
CLINICAL EXAMINATION
(Table A1)
Skin lesions and anaesthetic areas
Tactile sensation: a light static touch with cotton wool is recommended.19
Pain sensation: pin prick using a disposable pin or tooth pick.20
Temperature sensation: testing is not considered practical in peripheral health centres.
Autonomic function: look for loss of hair growth and loss of sweating.
Nerve palpation
Although nerve palpation is subjective and requires expertise, it is still considered a valuable
parameter for clinical evaluation of the patient. The only two studies available on reliability
of nerve palpation (ulnar, and common peroneal) showed only moderate or poor reliability.21
There is evidence that the common peroneal (CP) nerve is commonly affected distally on the
dorsum of the foot. Likewise, there is evidence that the radial cutaneous (RC) and sural
nerves are commonly affected (INFIR study).2 These nerves are not routinely assessed in the
clinical examination of leprosy patients. The group recommends that the following nerves
should be palpated in diagnostic and follow up examinations: greater auricular, ulnar, RC and
CP nerves. They should be evaluated for size, tenderness and consistency. Other nerves that
may be included, depending on expertise and guidelines are median, posterior tibial (PT) and
sural nerves.
NERVE FUNCTION ASSESSMENT (NFA)
(Table A2)
Autonomic function
Evaluate skin dryness, hair loss and skin colour and temperature of palms and soles.
Sensory function
Tactile sensation Testing of tactile sensation can be performed with a ballpoint pen, but if
possible, the use of graded nylon monofilaments is preferred.22 – 24
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Pain Pin prick using a disposable pin or tooth pick (the pin or tooth pick should be disposed
after use to prevent accidental transmission of any infectious diseases).
Temperature Temperature sensation: testing is not considered practical in peripheral health
centres.
For the three types of sensation, pain, temperature and tactile, it is recommended to
evaluate two sites per nerve for ulnar, median, RC and sural nerves, and 4 sites for PT nerve.
Note the presence of callous and scars and exclude these as testing sites.
Motor function
Evaluate the presence of muscle atrophy (thenar, hypothenar regions) and of the common
paralytic deformities, such as foot or wrist drop, claw fingers, and lagophthalmos. Perform
one voluntary muscle test (VMT) each for facial, ulnar, median and CP nerves using the 3
grades: Strong, Weak and Paralysed.
REFERRAL CENTRE LEVEL
At the referral centre, the patient should be evaluated by staff specialised in managing leprosy
complications, if possible a neurologist and/or other specialists as required according to the
patient’s condition (Table A3).
CLINICAL EXAMINATION
As above
NERVE FUNCTION ASSESSMENT
Autonomic function
Evaluate skin dryness, hair loss and skin colour and temperature of palms and soles. If
equipment is available, vasomotor reflexes may be tested with laser Doppler flowmetry.25,26
Sensory function
In addition to the nerves evaluated at the field level, the facial nerve and CP branch on the
dorsum of the foot should be evaluated. Testing should be further refined and quantified by
using several graded monofilaments.27 Proprioception and tendon reflexes are only important
for differential diagnosis.
Motor function
Voluntary muscle testing should include two strength tests each for facial, ulnar, median and
common peroneal nerves using the 6-grade scale (0–5).28 Consider adding tests for PT (big
toe flexion) and CP nerves (toe extension). Dynamometry could be added to quantify muscle
strength.
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ELECTROPHYSIOLOGICAL TESTING
The minimum parameters and nerves that should be tested are amplitude, latency and velocity
of sensory (ulnar, median, radial (cutaneous), sural) and motor (ulnar, median, radial,
peroneal) action potentials. The technique should be standardized for all studies in leprosy,
including standard test sites for each nerve.
FREQUENCY OF NERVE FUNCTION ASSESSMENT
NFA should be performed as part of the diagnostic examination and, subsequently, to monitor
the response to treatment and occurrence of complications. Considering that early diagnosis
of NFI is the main intervention available for prevention of permanent NFI, the minimum
frequency of NFA should be standardised to monitor nerve function and allow early detection
of NFI. The group concluded that NFA should be performed at different times and
frequencies according to the type of leprosy, the presence of NFI and the context of the case
management:
. NFA should be performed at leprosy diagnosis and at the end of treatment with MDT for
all types of the disease.
. In case NFI is present at diagnosis, NFA should be performed at every visit.
. PB patients should be examined at least at diagnosis and at the time of release from
treatment.
. In MB patients, the assessment should continue after MDT every 3 months for 2 years.
. MB patients with NFI should be referred when feasible for more detailed evaluation.
Research Priorities
1. Diagnosis
The pathophysiology of nerve damage should be studied further. This may result in
improvements in existing testing techniques and/or different techniques for the detection
of (early, sub-clinical) leprosy and nerve involvement. A diagnostic algorithm for leprosy
should be developed (definite, probably, possible, unlikely). The algorithm could include
nerve conduction tests and, if possible, an EMG with needle electrodes, which would aid
in differentiating leprosy from other neurological diseases, and acute neuritis from
neuropathic pain.
Research questions include:
. What are the earliest neurological signs of leprosy, including in leprosy contacts?
. What are the most sensitive (earliest affected) handheld sensory tests for diagnosing
leprosy and NFI?
. What is the value of nerve conduction studies (NCS) in the diagnosis of leprosy in
contacts of patients?
2. Clinical testing
To increase effectiveness of testing in the diagnosis of NFI and diagnosis of the
disease, there is a need to establish a consensus of best combination of nerves to be
included in clinical NFA. The possible role of vibrometry (including tuning fork(s))
and thermal sensation testing in the assessment of nerve function needs further
research.
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Research questions include:
. Are big toe flexion and extension strength tests useful in the assessment and
evaluation of the PT and CP motor nerve function (intrinsic muscles of the foot)?
. What is the value of skin wrinkling and finger printing tests in assessing
autonomic function?
. What is the clinical value of sensory testing of face, elbows and knees in the
diagnosis (treatment follow-up) of leprosy?
3. Complementary tests to validate clinical testing
Nerve function
The place of dynamometry in evaluating motor function (e.g. RIHM, Rotterdam
Intrinsic Hand Myometer) should be studied further in relation to VMT using the
MRC scale. The question is: how findings on dynamometry correlate with VMT and
with motor nerve conduction?
Nerve size (palpation)
Nerve enlargement is a fairly subjective finding and the reliability of nerve
palpation is questioned. Therefore, findings of nerve palpation (size) need to be
compared and validated with imaging techniques, such as ultrasound and MRI.
Electrophysiology
Several questions emerged that require further investigation regarding NCS.
. What is the correlation between NCS and histopathological findings?
. What is the value of Motor Unit Number Evaluation (MUNE) in leprosy? How
does the MUNE technique that measures the approximate number of motor
neurons innervating a single muscle or a small group of muscles, relate to clinical
muscle testing? Can progressive motor unit loss produced by leprosy reactions be
evaluated by MUNE?
4. Treatment monitoring
The prognostic advantage of early detection of sub-clinical neuropathy should be
demonstrated in a double blind randomised controlled trial. Available evidence
suggests that NCS and testing of thermal sensation should be included when
monitoring any clinical trial of treatment of NFI, as well as in future cohort studies
investigating neurological outcomes.
5. Analysis of existing data
Additional analysis of INFIR/BANDS/TRIPOD data, and possibly other studies, is
recommended to a) provide additional justification for the inclusion of other nerves in NFA
(field or research) and b) determine if the number of sensory test sites can be reduced
without losing the sensitivity of the test (when compared to a reference test with 10 test
sites).
IMPLICATIONS FOR TREATMENT – GROUP 3
Optimal steroid treatment (duration/dosage/delivery)
There is evidence that the WHO-recommended 12-week steroid regimen produces poorer
nerve function impairment outcomes than a 20-week regimen.29 A recent RCT has shown
that for Type 1 Reactions, treatment for 20 weeks produced significantly better outcomes than
the 12-week treatment.30 There was no difference in outcomes between a high-dose regimen,
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starting at 60 mg per day and a lower-dose regimen starting at 30 mg per day. For Type 2
Reactions it is probably better to start with higher initial doses of 60 mg.
There have been no RCTs of standardised or patient-tailored steroid regimens that have
Nerve Function Impairment as the primary outcome or of a comparison between these two
approaches. Steroid regimens have been shown to be beneficial for ‘simple’ one-episode
neuritis, but disappointing for recurrent neuritis.31 Furthermore, it is not clear whether a
recurrent neuritis should be considered a treatment failure or an additional episode of neuritis.
Long-term benefits of steroids on nerve function impairment measures are not well
established. Another gap in current knowledge concerns the treatment of silent neuritis.
Based on current evidence we recommend giving a minimum of 20 weeks steroids for
leprosy reactions, with a starting dose of 0·5–1 mg/kg body weight (in most leprosy-endemic
countries usually between 30–60 mg), and then slowly reducing the dose. The patient’s nerve
function is monitored at least every 4 weeks.
Other immunosuppressants
The role of other immunosuppressants is currently being defined in relation to:
. Efficacy in improving nerve function
. Efficacy in treating patients not responding to steroids
. Patients with contra-indications to steroids
Clinical trials have shown the usefulness of azathioprine and cyclosporine,32,33 and
there is an ongoing study in Nepal using methylprednisolone-pulse-therapy at the start of
treatment for reactions. A large RCT using azathioprine in Type 1 reactions is starting in
India. Studies are being planned for Ethiopia; including trials concerning the usefulness of
treatment with single immunosuppressants; others looking at the effect of combinations of
immunosuppressants. RCTs are needed to establish their efficacy in the treatment of acute
neuritis.
The role of other immunosuppressants in the management of Type 2 reactions is also
being investigated. Several studies are in early stages or being planned, azathioprine in India,
cyclosporine in the Philippines and methotrexate in Sri Lanka.
Neuropathic pain
Neuropathic pain is pain due to a primary lesion or dysfunction in the peripheral or
central nervous system. The term neurogenic pain is sometimes used if the dysfunction
causing pain is reversible. Hence, neuropathic pain always indicates permanent
abnormality. It was observed that, although a frequent clinical problem, neuropathic
pain in leprosy, particularly chronic post-inflammatory pain, has received insufficient
attention.34 – 37 Pain related to acute neuritis is neurogenic pain because it is usually
reversible. Little is known about the mechanisms of neuropathic pain in leprosy. No
Randomised Controlled Trials (RCT) have been done for the treatment of leprosy-related
neuropathic pain.
Several interventions were identified that may relieve neuropathic pain in leprosy, such as
pain medication, physiotherapy, surgery and patient counselling. Studies should also be
designed to ensure that the potential placebo effects can be detected.
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Based on general management of neuropathic pain and recommendations in Brazil for
treatment of neuropathic pain in leprosy, the following medical treatments may be
beneficial:38
. Amitriptyline 10–150 mg/day
. Nortriptyline: 10–150 mg/day
. Gabapentin: 900–3600 mg/day, divided over 3 doses
. Carbamazepine 200–600 mg/day, divided over 2–3 doses
We recommend starting treatment with either amitriptyline or nortriptyline as a first line
drug if there are no contraindications. Patients with narrow-angle glaucoma, prostatic
hyperplasia and heart disease should be treated with caution. The drug is started at a low dose,
10–25 mg in the evening, and the dose is increased in steps of 10–25 mg after 3–7 days to an
adequate level of pain relief, with a maximum dose up to 150 mg/day.
Gabapentin is administered three times a day, and the target dose in the treatment of pain
is 900–3600 mg/day. The initial dose is 300 mg at bedtime, and the dose can be increased
with 300 mg in 1–3 days. Carbamazepine may be useful in throbbing or electric shock-like
pain. It is started with 100 mg at bedtime and increased in steps of 100 mg after 3–5 days. The
maintenance dose in neuropathic pain is usually 400–600 mg/day, divided into two doses
when a slow-release preparation is used and into three doses when an ordinary preparation is
used. Blood count and sodium and transaminase levels should be monitored, at least at the
start of treatment.
Identification of high-risk groups for neuritis
Research shows that some leprosy patients are at higher risk of developing NFI, especially
patients with MB leprosy, those with NFI at diagnosis and those with detectable PGL-1
antibodies.
Current knowledge shows that the following patients should have their nerve function
closely monitored during and after MDT:4
. PB patients with pre-existing NFI
. MB patients without NFI (1 year monitoring after registration)
. MB patients with pre-existing NFI (2 year monitoring after registration)
At present, prophylaxis with steroids to prevent NFI cannot be recommended, as current
evidence shows that 20 mg of prednisolone per day given for 16 weeks, although beneficial at
16 weeks, was not beneficial at the end of one year (TRIPOD trials).39 Therefore, further
studies are desirable. In such studies the possible benefit of using prophylaxis with steroid
must be carefully balanced against possible risks of using steroids.
Surgery
In the literature there is anecdotal evidence that surgery might have a role in the management
of acute and chronic neuropathic pain.40 Its indications, however, are not standardised, nor
have there been conclusive clinical trials to prove its efficacy. Notwithstanding, we see a
possible role for surgery for patients with severe nerve pain who do not respond to medical
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treatment and for those whose nerve function has not improved or is deteriorating during or
after steroid treatment. To make further progress in this area, the mechanisms of pain in
leprosy should be better understood, and hypotheses developed as to which types of pain
might benefit from surgery.
Other questions
Many other questions are still left to be answered, e.g., what is the potential of nerve
regeneration factors in the treatment of nerve damage in leprosy? Is there any rationale for
using different treatment approaches for neuritis caused by Type 1 or Type 2 reaction? What
are the options for the management of recurrent neuritis?
Research Priorities
1. Steroid treatment
. A multi-centre RCT that compares different durations and dosages of steroids with
nerve function as primary outcome. It is important to have a large enough study to
permit sub-group analysis, especially for differing nerve status at entry.
. An RCT comparing patient tailored steroid schemes with a standardised steroid
regimen of at least 20 weeks (see above).
2. Neuropathic pain
. Epidemiological studies on neuropathic pain in leprosy patients
. Clinical trials to assess the efficacy of the general pain management, as indicated
above, in the management of leprosy-associated neuropathic pain.
3. Steroid prophylaxis
. A multi-centre RCT to see whether subgroups of patients can be identified who would
benefit from prophylaxis with steroids to prevent NFI.
. A multi-centre RCT to investigate whether prophylaxis of longer duration would be
beneficial in defined subgroups.
4. Other immunosuppressants
RCTs are needed to establish the efficacy of immunosuppressants, such as azathioprine
and cyclosporine, in the treatment of acute neuritis.
5. Neurolysis
A multi-centre RCT to investigate the efficacy of neurolysis surgery in patients with
NFI .6 months, non-responders to steroids and other inclusion criteria are needed with a
clear consensus about treatment outcome measures. These might include monofilament
assessments of sensory function, nerve conduction studies and measuring of intra-neural
pressure.
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Appendix 1 – Consensus statement on handling of nerve biopsies
The following is a guideline, not a protocol.
Nerve biopsies (1–1·5 cm) should be processed immediately as follows. The specimen
should be divided into 4 pieces: The two end pieces should be placed in 10% buffered
formalin for routine histopathology; a central piece (approx 2 mm) in EM fixative for electron
microscopy; and the last piece snap frozen for histochemical, biochemical, or molecular
studies. Projects planning to obtain nerve biopsies routinely should consult a pathologist
experienced with nerve biopsies to finalize a detailed protocol for the study.
Appendix 2 – Tables of recommended neurological tests
Table A1. Neurological tests recommended for a diagnostic examination of leprosy in peripheral health centres
Function Tools/tests Site Grading
Sensory Pinprick: toothpick or disposable
pin
Skin Yes/no
Ballpoint pen Skin Yes/no
Cotton wool Skin Yes/no
Motor Presence of atrophy Thenar area Yes/no
Hypothenar area Yes/no
First web space Yes/no
Foot dorsum Yes/no
Contractures Eyes/hands/feet Yes/no
Voluntary muscle testing Facial, ulnar, median, radial and
common peroneal nerves
Strong/weak/paralysed
Autonomic Hair loss Skin Yes/no
Dryness Skin Yes/no
Nerve palpation Enlarged/tender Greater auricular, ulnar, radial
cutaneous, common peroneal and
posterior tibial nerves
Yes/no
Table A2. Neurological tests recommended for nerve function assessment of leprosy patients in peripheral health
centres
Function Tools/tests Site Grading
Sensory Ballpoint pen or Cotton wool (or
monofilaments when available)
2 sites per nerve for ulnar,
median, radial cutaneous
Yes/no
4 sites for posterior tibial Yes/no
2 sites for sural Yes/no
Motor Presence of atrophy As above Yes/no
Contractures Eyes/hands/feet Yes/no
Voluntary muscle testing Facial, ulnar, median, radial and
common peroneal nerves
Strong/weak/paralysed
Autonomic Feel for dryness Palms and soles Yes/no
Nerve palpation Enlarged/tender Greater auricular, ulnar, radial
cutaneous, common peroneal and
posterior tibial nerves
Yes/no
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Table A3. Neurological tests recommended for nerve function assessment of leprosy patients in referral centres
Function Tools/tests Site Grading
Sensory Pain with pin-prick Dermatomes and nerves (ulnar,
median, radial, posterior tibial,
sural)
Yes/no/diminished
Cold/warm Dermatomes and nerves (ulnar,
median, radial, posterior tibial,
sural)
Yes/no/diminished
Light touch with cotton wool Dermatomes and nerves (ulnar,
median, radial, posterior tibial,
sural)
Yes/no/diminished
Vibrometry: tuning fork Wrists, elbows, clavicles medial
malleoli, patellas
Yes/no/diminished
Deep tendon reflexes Biceps, triceps, brachioradialis,
patellar, achillean
0–4
Monofilaments 3 sites per nerve for ulnar,
median, radial, and sural; 4 sites
for posterior tibial
0–5
Nerve conduction studies Facial, ulnar, radial, median, sural Amplitude
Latency
Velocity
Temporal dispersion
Motor Blink reflex Facial nerve Latency
Voluntary muscle testing Ulnar, median, radial, posterior
tibial, common peroneal
0–5
Nerve conduction studies Facial, ulnar, median, radial,
common peroneal, tibial
Amplitude
Latency
Velocity
Temporal dispersion
Autonomic Laser Doppler fluxometry Fingertips and toes Vasomotor reflexes
Nerve palpation Enlarged/tender Greater auricular, ulnar, radial
cutaneous, common peroneal and
posterior tibial nerves
Yes/no
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Appendix 3: Workshop participants
Table A4.
Name Affiliation and country
1 Dr Ximena Illarramendi Oswaldo Cruz Institute, FIOCRUZ, Brasil
2 Dr Se´rgio Luiz Gomes Antunes Oswaldo Cruz Institute, FIOCRUZ, Brasil
3 Dr Wilson Marques Junior Universidade de Sa˜o Paulo, Brasil
4 Dr Marcos Raimundo Gomes
de Freitas
Universidade Federal Fluminense, Brasil
5 Dr Jose´ Antoˆnio Garbino Instituto Lauro de Souza Lima, Brasil
6 Dr J. Wim Brandsma ALERT, Ethiopia
7 Dr Elizabeth Bizuneh ALERT, Ethiopia
8 Dr P.S.S. Sundar Rao The Leprosy Mission Trust India
9 Dr Rupendra Jadav Stanley Browne Labs, India
10 Dr Lavanya Suneetha Nireekshana-acet Narayanaguda, India
11 Dr Sujai Suneetha Nireekshana, India
12 Prof Indira Nath Blue Peter Research Centre, India
13 Dr Vanaja Shetty The Foundation for Medical Research, India
14 Dr Sajid Husain Central JALMA Institute for Leprosy, India
15 Dr Amit Agrawal Datta Meghe Institute of Medical Sciences, India
16 Dr Mary Jacob Christian Medical College, India
17 Dr Murdo Macdonald Mycobacterial Research Laboratory, Nepal
18 Dr Einar Wilder-Smith National University Hospital, Singapore
19 Dr David Pahan Rural health programmes DBLM, Bangladesh
20 Dr David Scollard National Hansen’s Disease Programs, USA
21 Dr Paul Saunderson ALM, Norway
22 Dr Erik Post DAHW (GLRA), Germany
23 Prof W. Cairns S. Smith University of Aberdeen, UK
24 Prof Diana N.J. Lockwood London School of Hygiene and Tropical Medicine, UK
25 Dr Steve Walker London School of Hygiene and Tropical Medicine, UK
26 Dr Indira Kahawita London School of Hygiene and Tropical Medicine, UK
27 Mr Jason Mcknight London School of Hygiene and Tropical Medicine, UK
28 Dr Peter Nicholls University of Southampton, UK
29 Dr Aki Hietaharju Tampere University Hospital, Finland
30 Dr Wim van Brakel Royal Tropical Institute (KIT), Netherlands
31 Dr Remke Jellema Netherlands Leprosy Relief, Netherlands
32 Dr Jan Hendrik Richardus Erasmus MC, University Medical Center Rotterdam, Netherlands
33 Ms Natasja van Veen Erasmus MC, University Medical Center Rotterdam, Netherlands
34 Prof Tom Ottenhoff Leiden University Medical College, Netherlands
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